Cargando…
Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study
BACKGROUND: Myeloproliferative neoplasms (MPNs) are a group of myeloid malignancies associated with significant symptom burden. Despite pharmacological advances in therapies, inadequate management of MPN symptoms results in reduced quality of life. OBJECTIVE: This study aims to determine the feasibi...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JMIR Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015738/ https://www.ncbi.nlm.nih.gov/pubmed/35357315 http://dx.doi.org/10.2196/33581 |
_version_ | 1784688373728804864 |
---|---|
author | Win, Hninyee Russell, Samantha Wertheim, Betsy C Maizes, Victoria Crocker, Robert Brooks, Audrey J Mesa, Ruben Huberty, Jennifer Geyer, Holly Eckert, Ryan Larsen, Ashley Gowin, Krisstina |
author_facet | Win, Hninyee Russell, Samantha Wertheim, Betsy C Maizes, Victoria Crocker, Robert Brooks, Audrey J Mesa, Ruben Huberty, Jennifer Geyer, Holly Eckert, Ryan Larsen, Ashley Gowin, Krisstina |
author_sort | Win, Hninyee |
collection | PubMed |
description | BACKGROUND: Myeloproliferative neoplasms (MPNs) are a group of myeloid malignancies associated with significant symptom burden. Despite pharmacological advances in therapies, inadequate management of MPN symptoms results in reduced quality of life. OBJECTIVE: This study aims to determine the feasibility of a 12-week global wellness mobile app intervention in decreasing MPN symptom burden. The University of Arizona Andrew Weil Center for Integrative Medicine’s global wellness mobile app, My Wellness Coach (MWC), guides patients to improve their health and well-being through facilitating behavior changes. METHODS: Of the 30 patients enrolled in a 12-week intervention, 16 (53%) were retained through the final assessment. Feasibility was assessed by the ease of recruitment, participant adherence, and mobile app acceptability. App acceptability was measured using the user version of the Mobile Application Rating Scale. MPN symptom burden was measured at baseline and 12 weeks after the intervention. RESULTS: Recruitment was efficient, with the participant goal reached within a 60-day period, suggestive of a demand for such an intervention. Adherence was less than the target within study design (75%), although similar to mobile device app use in other studies (53%). The app was deemed acceptable based on the mean user version of the Mobile Application Rating Scale 3-star rating by participants. Finally, there were statistically significant improvements in several MPN symptoms, quality of life, and total score on the Myeloproliferative Neoplasm Symptom Assessment Form surveys. CONCLUSIONS: Our 12-week intervention with the MWC app was feasible and was associated with a decrease in MPN symptom burden. Further investigation of the MWC app for use as a self-management strategy to reduce the symptom burden in patients with MPN is warranted. |
format | Online Article Text |
id | pubmed-9015738 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | JMIR Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-90157382022-04-19 Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study Win, Hninyee Russell, Samantha Wertheim, Betsy C Maizes, Victoria Crocker, Robert Brooks, Audrey J Mesa, Ruben Huberty, Jennifer Geyer, Holly Eckert, Ryan Larsen, Ashley Gowin, Krisstina JMIR Form Res Original Paper BACKGROUND: Myeloproliferative neoplasms (MPNs) are a group of myeloid malignancies associated with significant symptom burden. Despite pharmacological advances in therapies, inadequate management of MPN symptoms results in reduced quality of life. OBJECTIVE: This study aims to determine the feasibility of a 12-week global wellness mobile app intervention in decreasing MPN symptom burden. The University of Arizona Andrew Weil Center for Integrative Medicine’s global wellness mobile app, My Wellness Coach (MWC), guides patients to improve their health and well-being through facilitating behavior changes. METHODS: Of the 30 patients enrolled in a 12-week intervention, 16 (53%) were retained through the final assessment. Feasibility was assessed by the ease of recruitment, participant adherence, and mobile app acceptability. App acceptability was measured using the user version of the Mobile Application Rating Scale. MPN symptom burden was measured at baseline and 12 weeks after the intervention. RESULTS: Recruitment was efficient, with the participant goal reached within a 60-day period, suggestive of a demand for such an intervention. Adherence was less than the target within study design (75%), although similar to mobile device app use in other studies (53%). The app was deemed acceptable based on the mean user version of the Mobile Application Rating Scale 3-star rating by participants. Finally, there were statistically significant improvements in several MPN symptoms, quality of life, and total score on the Myeloproliferative Neoplasm Symptom Assessment Form surveys. CONCLUSIONS: Our 12-week intervention with the MWC app was feasible and was associated with a decrease in MPN symptom burden. Further investigation of the MWC app for use as a self-management strategy to reduce the symptom burden in patients with MPN is warranted. JMIR Publications 2022-03-31 /pmc/articles/PMC9015738/ /pubmed/35357315 http://dx.doi.org/10.2196/33581 Text en ©Hninyee Win, Samantha Russell, Betsy C Wertheim, Victoria Maizes, Robert Crocker, Audrey J Brooks, Ruben Mesa, Jennifer Huberty, Holly Geyer, Ryan Eckert, Ashley Larsen, Krisstina Gowin. Originally published in JMIR Formative Research (https://formative.jmir.org), 31.03.2022. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Formative Research, is properly cited. The complete bibliographic information, a link to the original publication on https://formative.jmir.org, as well as this copyright and license information must be included. |
spellingShingle | Original Paper Win, Hninyee Russell, Samantha Wertheim, Betsy C Maizes, Victoria Crocker, Robert Brooks, Audrey J Mesa, Ruben Huberty, Jennifer Geyer, Holly Eckert, Ryan Larsen, Ashley Gowin, Krisstina Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study |
title | Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study |
title_full | Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study |
title_fullStr | Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study |
title_full_unstemmed | Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study |
title_short | Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study |
title_sort | mobile app intervention on reducing the myeloproliferative neoplasm symptom burden: pilot feasibility and acceptability study |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015738/ https://www.ncbi.nlm.nih.gov/pubmed/35357315 http://dx.doi.org/10.2196/33581 |
work_keys_str_mv | AT winhninyee mobileappinterventiononreducingthemyeloproliferativeneoplasmsymptomburdenpilotfeasibilityandacceptabilitystudy AT russellsamantha mobileappinterventiononreducingthemyeloproliferativeneoplasmsymptomburdenpilotfeasibilityandacceptabilitystudy AT wertheimbetsyc mobileappinterventiononreducingthemyeloproliferativeneoplasmsymptomburdenpilotfeasibilityandacceptabilitystudy AT maizesvictoria mobileappinterventiononreducingthemyeloproliferativeneoplasmsymptomburdenpilotfeasibilityandacceptabilitystudy AT crockerrobert mobileappinterventiononreducingthemyeloproliferativeneoplasmsymptomburdenpilotfeasibilityandacceptabilitystudy AT brooksaudreyj mobileappinterventiononreducingthemyeloproliferativeneoplasmsymptomburdenpilotfeasibilityandacceptabilitystudy AT mesaruben mobileappinterventiononreducingthemyeloproliferativeneoplasmsymptomburdenpilotfeasibilityandacceptabilitystudy AT hubertyjennifer mobileappinterventiononreducingthemyeloproliferativeneoplasmsymptomburdenpilotfeasibilityandacceptabilitystudy AT geyerholly mobileappinterventiononreducingthemyeloproliferativeneoplasmsymptomburdenpilotfeasibilityandacceptabilitystudy AT eckertryan mobileappinterventiononreducingthemyeloproliferativeneoplasmsymptomburdenpilotfeasibilityandacceptabilitystudy AT larsenashley mobileappinterventiononreducingthemyeloproliferativeneoplasmsymptomburdenpilotfeasibilityandacceptabilitystudy AT gowinkrisstina mobileappinterventiononreducingthemyeloproliferativeneoplasmsymptomburdenpilotfeasibilityandacceptabilitystudy |